GlyProVac
GlyProVac is pursuing the development of a glycoprotein based vaccine against Enterotoxigenic Escherichia coli (ETEC).
GlyProVac is active in the biopharma space based in European Union (EU), Nordic Countries, Scandinavia, Europe, Middle East, and Africa (EMEA), founded in 2018.
Its activity falls under biopharma; the profile below is assembled from public directory data.
European Union (EU), Nordic Countries, Scandinavia, Europe, Middle East, and Africa (EMEA) is where the company is located.
The company is listed at the Grant stage of development.
It has disclosed roughly $467K in funding.
| Sector | Biopharma |
|---|---|
| Headquarters | European Union (EU), Nordic Countries, Scandinavia, Europe, Middle East, and Africa (EMEA) |
| Founded | 2018 |
| Stage | grant |
| Total funding | $467,000 |
Website: glyprovac.com
Browse related
Contact details and direct channels are available to signed-in members.
Create a free account
Create a free account